Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial

Q: What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial, RCT).

Jing Zhang; Peng Wang; Yin Ren; Li Chen; JIn Feng; Fei Liu; Kaiwen Deng; Zhaoshi Bao; Xiaoguang Qiu; Yanwei Liu

doi:10.1002/cncr.70171

December 1, 2025Cancer

Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial

View at Publisher

Ask AI

Bookmark

Share

Key Points

Overall survival was significantly better with chemoradiotherapy compared to radiotherapy alone, enhancing treatment outcomes.
Progression-free survival rates were higher in patients receiving chemoradiotherapy with temozolomide over those treated with radiotherapy alone.
The retrospective analysis evaluated patients diagnosed with IDH wild-type gliomas, highlighting the role of molecular markers in treatment efficacy.
Findings suggest that chemoradiotherapy could be a preferred treatment option for patients with specific glioma mutations.

Implication

Retrospective analysis shows improved survival in IDH wild-type gliomas with temozolomide, indicating benefits of combined therapy.

Abstract

The long‐term results confirmed that the OS and PFS benefits from the RT‐TMZ exceeded those of the RT alone in patients with IDH‐wt/pTERTmut gliomas with tolerable toxicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/6930e8cdea1aef094cca390e https://doi.org/10.1002/cncr.70171

View at Publisher

Ask AI

Bookmark

Share

Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading